- Home
- ETNB vs FORTY Comparison
ETNB vs FORTY Comparison
Compare ETNB & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- FORTY
- Stock Information
- Founded
- ETNB 2018
- FORTY 1985
- Country
- ETNB United States
- FORTY Israel
- Employees
- ETNB N/A
- FORTY N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- FORTY EDP Services
- Sector
- ETNB Health Care
- FORTY Technology
- Exchange
- ETNB Nasdaq
- FORTY Nasdaq
- Market Cap
- ETNB 2.2B
- FORTY 2.3B
- IPO Year
- ETNB 2019
- FORTY 1997
- Fundamental
- Price
- ETNB $14.80
- FORTY N/A
- Analyst Decision
- ETNB Buy
- FORTY
- Analyst Count
- ETNB 10
- FORTY 0
- Target Price
- ETNB $22.31
- FORTY N/A
- AVG Volume (30 Days)
- ETNB 3.5M
- FORTY 380.0
- Earning Date
- ETNB 11-07-2025
- FORTY 11-20-2025
- Dividend Yield
- ETNB N/A
- FORTY 0.94%
- EPS Growth
- ETNB N/A
- FORTY 15.06
- EPS
- ETNB N/A
- FORTY 4.97
- Revenue
- ETNB N/A
- FORTY $2,889,481,000.00
- Revenue This Year
- ETNB N/A
- FORTY N/A
- Revenue Next Year
- ETNB N/A
- FORTY N/A
- P/E Ratio
- ETNB N/A
- FORTY $28.36
- Revenue Growth
- ETNB N/A
- FORTY 8.58
- 52 Week Low
- ETNB $4.16
- FORTY $77.50
- 52 Week High
- ETNB $15.06
- FORTY $151.31
- Technical
- Relative Strength Index (RSI)
- ETNB 75.79
- FORTY 61.34
- Support Level
- ETNB $14.74
- FORTY $131.23
- Resistance Level
- ETNB $14.85
- FORTY $151.31
- Average True Range (ATR)
- ETNB 0.06
- FORTY 0.95
- MACD
- ETNB -0.20
- FORTY 0.42
- Stochastic Oscillator
- ETNB 33.33
- FORTY 61.06
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About FORTY Formula Systems (1985) Ltd.
Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources, Michpal, ZAP Group, and Others. The majority of the company's revenue comes from Israel.